Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Forty Seven

Forty Seven
2014 FOUNDED
PUBLIC STATUS
51-60 EMPLOYEES
FTSV STOCK SYMBOL
1 INVESTMENTS
$12.15 SHARE PRICE (As of Friday Closing)
Description

Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Stock Exchange
NAS
Primary Office
  • 1490 O'Brien Drive
  • Suite A
  • Menlo Park, CA 94025
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Forty Seven’s full profile, request a free trial.

Forty Seven Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$10.50 - $23.83 $381M $12.16 -$4.09 193K 31.4M

Forty Seven Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 516,059 550,098
Revenue 0 0 0 0
EBITDA (80,398) (71,704) (44,933) (19,483)
Net Income (78,611) (70,370) (44,898) (19,539)
Total Assets 130,311 149,437 95,465 16,988
Total Debt 331 476 570
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Forty Seven Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Forty Seven‘s full profile, request access.

Request full access to PitchBook

Forty Seven Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Forty Seven‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Forty Seven Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avrobio Formerly VC-backed Cambridge, MA 00 00000 00000000000 00000
0000000 Venture Capital-Backed Cambridge, MA 0000 00000000000 0000
000000 Formerly VC-backed Lexington, MA 000 00000 000000000 00000
00000000000 000000 Formerly VC-backed Abingdon, United Kingdom 000 00000 00000000000 00000
000000 000000 Formerly VC-backed Seattle, WA 00 00000 000000&0 00000
To view this company’s complete list of competitors, request access »

Forty Seven Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000000 ( 01-Jun-2018 000000000 00000 00 Pharmaceuticals
To view this company’s complete investment and acquisition history, request access »

Forty Seven Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Forty Seven‘s full profile, request access.

Request full access to PitchBook

Forty Seven Executive Team (11)

Name Title Board
Seat
Contact
Info
Mark McCamish Ph.D President, Chief Executive Officer & Board Member
Ann Rhoads Chief Financial Officer
Irv Weissman MD Co-Founder & Board of Director
Craig Gibbs Ph.D Chief Business Officer
Norman Kruse JD Chief Patent Counsel

2 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

Forty Seven Board Members (8)

Name Representing Role Since Contact
Info
Christopher Schaepe Lightspeed Venture Partners Board Member 000 0000
Dennis Henner Ph.D Clarus Ventures Board Member 000 0000
Ian Clark Forty Seven Board Member 000 0000
Jeffrey Bird Ph.D Sutter Hill Ventures Board Member 000 0000
Jonathan MacQuitty Ph.D Lightspeed Venture Partners Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »